Clinical Trial Update: Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects [Phase 4]

View source ↗

Summary

Phase 4 post-authorization safety, tolerability, and immunogenicity evaluation of HyQvia in pediatric primary immunodeficiency disease patients has been complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• HYQVIA (immunoglobulin G (IgG) with recombinant human hyaluronidase)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 4 | Status: COMPLETED | Results posted: 2023-01-11